• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Phenotype analysis of perlecan mutated mice in which heparan sulfates are removed by the use of ES cell.

Research Project

Project/Area Number 11671052
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Kidney internal medicine
Research InstitutionShowa University

Principal Investigator

MORITA Hiroyuki  Showa University, School of Medicine, Associate professor, 医学部, 講師 (00311994)

Co-Investigator(Kenkyū-buntansha) KIMATA Koji  Aich Medical University, Institute for Molecular Science of Medicine, Professor, 分子医科学研究所, 教授 (10022641)
Project Period (FY) 1999 – 2000
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2000: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1999: ¥2,300,000 (Direct Cost: ¥2,300,000)
Keywordscharge barrier / heparan sulfate proteoglycans / perlecan / gene targeting / homozygous mouse / GBM / negative charge theory / proteinuria / 糸球体ろ過 / チャ-ジバリア / パーリカン / 遺伝子ターゲティング
Research Abstract

In the process of glomerular filtration, glomerular basement membranes (GBM) serve as a charge barrier to retain negatively-charged macromolecules in the circulation. On the molecular basis, GBM heparan sulfate prteoglycans (HSPG) have been thought of as key components that constitute the barrier. This negative charge theory has long been generally accepted. However, there is no direct evidence at the molecular level which links the collapse of the barrier to the development of proteinuria. Perlecan is a major GBM HSPG. Perlecan encompasses five molecular domains. Exon 3 of the first domain encodes heparan sulfate attachment sites. The present study was designed to evaluate negative charge theory from a different perspective. By the use of embryonic stem (ES) cell technology, the exon 3 was removed without frame shift. As a result, homozygous mouse was produced having mutated perlecan molecule. Our biochemical analysis at the post-transcriptional level demonstrated fibroblast obtained from the homozygote produed perlecan without heparan sulfates having an intact size of the core molecule. Although homozygotes did not spontaneously show massive proteinuria, intra-peritoneal albumin overload resulted in significant increase in urinary protein excretion after 2 weeks. Our immunoelectron microscopic investigation disclosed PEI stained sites in the GBM of homozygotes was not different from those of wild-type controls. The results strongly indicated other GBM HSPG compensate the loss of perlecan heparan sulfate. Agrin, another GBM HSPS, was not a candidate.

Report

(2 results)
  • 2001 Final Research Report Summary
  • 1999 Annual Research Report
  • Research Products

    (10 results)

All Other

All Publications (10 results)

  • [Publications] Yoshimura A, Morita H, et al.: "Effects of simvastatin on proliferative nephritis and cell-cycle protein"Kidney Int. S71. S84-S87 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Yokota N, Morita H., et al.: "Reveisibie nephritic syndrome in a patient with anyloia A anyloidosts of the kidney following Methicillin-hesistant Staphylococcus aurous infection"Nephron. 87. 177-181 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Liu Y, Morita H., et al.: "Increased expression of lysyl oxidase mRNA in progressive mesangial prolifecative nephritis in the cat"Showa Univ J Med Sci. 12. 219-225 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Tsuruta Y, Morita H., et al.: "Effects of pinfenidone on an acute phase of anti-Thy-1 nephritis"Clin Exp Nephrol. 4. 306-312 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Yoshimura Y, Morita, H et al: "Effects of simvastatin on Proliferative nephritis and cell-cycle protein"Kidney Int (Suppl). 71. S84-S87 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Yokota N, Mprita H et al: "Reversible nephrotic syndronie in a patient with amyloid A amyloidosis of the kidney fol lowing Methicillin-resistant Staphyl ococcus aureus infection"Nephron. 87. 177-181 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Liu Y, Morita H et al: "Increased expression of lysyl oxidase mRNA in progressive rnesangial proliferative nephritis in the rat."Showa Univ Med Sci. 12. 219-225 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Tsurata Y, Morita H et al: "Hfects of pirfenidone on An acute phase of anti-Tny-1 nephritis"Clin Exp Nephrol. 4. 306-312 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Yoshimura A, Morita M 他9名: "Effect of simvastatin on proliferative nephritis and cell-cycle protein expression"Kidney International. 56(Suppl 71). S84-S87 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 森田博之、木全弘治: "プロテオグリカンと腎疾患"病理と臨床. 18巻4号. (2000)

    • Related Report
      1999 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi